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Abstract. Probabilistic model checking is a formal verification tech-
nique that has been successfully applied to the analysis of systems from
a broad range of domains, including security and communication pro-
tocols, distributed algorithms and power management. In this paper we
illustrate its applicability to a complex biological system: the FGF (Fi-
broblast Growth Factor) signalling pathway. We give a detailed descrip-
tion of how this case study can be modelled in the probabilistic model
checker PRISM, discussing some of the issues that arise in doing so, and
show how we can thus examine a rich selection of quantitative properties
of this model. We present experimental results for the case study under
several different scenarios and provide a detailed analysis, illustrating
how this approach can be used to yield a better understanding of the
dynamics of the pathway.
1 Introduction
There has been considerable success recently in adapting approaches from com-
puter science to the analysis of biological systems and, in particular, biochemical
pathways. The majority of this work has relied on simulation-based techniques
developed for discrete stochastic models [7]. These allow modelling of the evolu-
tion of individual molecules, whose rates of interaction are controlled by exponen-
tial distributions. The principal alternative modelling paradigm, using ordinary
differential equations, differs in that it reasons about how the average concen-
trations of the molecules evolve over time. In this paper, as in [4,3], we adopt
the stochastic modelling approach, but employ methods which allow calculation
of exact quantitative measures of the model under study.
We use probabilistic model checking [19] and the probabilistic model checker
PRISM [9,14] as a framework for the modelling and analysis of biological path-
ways. This approach is motivated by the success of previous work which has
demonstrated the applicability of these techniques to the analysis of a wide va-
riety of complex systems [11]. One benefit of this is the ability to employ the
existing efficient implementations and tool support developed in this area. Ad-
ditionally, we enjoy the advantages of model checking, for example, the use of
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both a formal model and specification of the system under study and the fact
that the approach is exhaustive, that is, all possible behaviours of the system are
analysed. Our intention is that the methods in this paper should be used in con-
junction with the classical simulation and differential equation based approaches
to provide greater insight into the complex interactions of biological pathways.
This paper provides a detailed illustration of the applicability of probabilistic
model checking to this domain through the analysis of a complex biological
pathway called FGF (Fibroblast Growth Factor).
Related Work. The closest approach to that presented here is [4], where the
probabilistic model checker PRISM is used to model the RKIP inhibited ERK
pathway. The main difference is that in [4] the authors consider a “population”
based approach to modelling using approximate techniques where concentrations
are modelled by discrete abstract quantities. In addition, here we demonstrate
how a larger class of temporal properties including reward-based measures are
applicable to the study biological systems. Also related to the RKIP inhibited
ERK pathway is [3], where it is demonstrated how the stochastic process algebra
PEPA [8] can be used to model biological systems. The stochastic pi-calculus
[15] has been proposed as a model language for biological systems [18,16]; this
approach has so far been used in conjunction with stochastic simulation, for
example through the tools BioSpi [16] and SPiM [12].
In parallel with the development of the PRISM model of the FGF path-
way presented in this paper, we have constructed a separate pi-calculus model
[22,13] and applied stochastic simulation through BioSpi. Although currently
these works focus on different aspects of the pathway, in the future we aim
to use this complex case study as a basis for investigating the advantages of
stochastic simulation and probabilistic model checking.
2 Probabilistic Model Checking and PRISM
Probabilistic model checking is a formal verification technique for the modelling
and analysis of systems which exhibit stochastic behaviour. This technique is
a variant of model checking , a well-established and widely used formal method
for ascertaining the correctness of real-life systems. Model checking requires two
inputs: a description of the system in some high-level modelling formalism (such
as a Petri net or process algebra), and specification of one or more desired
properties of that system in temporal logic (e.g. CTL or LTL). From these,
one can construct a model of the system, typically a labelled state-transition
system in which each state represents a possible configuration and the transitions
represent the evolution of the system from one configuration to another over
time. It is then possible to automatically verify whether or not each property is
satisfied, based on a systematic and exhaustive exploration of the model.
In probabilistic model checking, the models are augmented with quantita-
tive information regarding the likelihood that transitions occur and the times
at which they do so. In practice, these models are typically Markov chains or
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Reactions:
1. A+B ←→ A:B (complexation)
2. A −→ (degradation)
Reaction rates:
- complexation : r1
- decomplexation : r2
- degradation : r3
(a) System of reactions
module M
ab : [0..2] init 1;
// 0: a degraded, b free 1: a,b free 2: a,b bound
[] ab=1 → r1 : (ab′=2); // bind
[] ab=2 → r2 : (ab′=1); // unbind
[] ab=1 → r3 : (ab′=0); // degrade
endmodule
(b) PRISM encoding 1
module A
a : [0..1] init 1;
[bind] a=1 → r1 : (a′=0);
[rel] a=0 → r2 : (a′=1);
[] a=1 → r3 : (a′=0);
endmodule
module B
b : [0..1] init 1;
[bind] b=1 → (b′=0);
[rel] b=0 → (b′=1);
endmodule
module AB
ab : [0..1] init 0;
[bind] ab=0 → (ab′=1);
[rel] ab=1 → (ab′=0);
endmodule
(c) PRISM encoding 2
rewards a=1 : 1; endrewards
(d) Reward structure 1
rewards [bind] true : 1; endrewards
(e) Reward structure 2
Fig. 1. Simple example and possible PRISM representations
Markov decision processes. In this paper, it suffices to consider continuous-time
Markov chains (CTMCs), in which transitions between states are assigned (posi-
tive, real-valued) rates, which are interpreted as the rates of negative exponential
distributions. The model is augmented with rewards associated with states and
transitions. Rewards associated with states (cumulated rewards) are incremented
in proportion to the time spent in the state, while rewards associated with tran-
sitions (impulse rewards) are incremented each time the transition is taken.
Properties of these models, while still expressed in temporal logic, are now
quantitative in nature. For example, rather than verifying that “the protein
always eventually degrades”, we may ask “what is the probability that the pro-
tein eventually degrades?” or “what is the probability that the protein degrades
within T hours?”. Reward-based properties include “what is the expected energy
dissipation within the first T time units?” and “what is the expected number of
complexation reactions before relocation occurs?”.
PRISM [9,14] is a probabilistic checking tool developed at the University
of Birmingham. Models are specified in a simple state-based language based on
Reactive Modules. An extension of the temporal logic CSL [1,2] is used to specify
properties of CTMC models augmented with rewards. The tool employs state-
of-the-art symbolic approaches using data structures based on binary decision
diagrams [10]. Also of interest, the tool includes support for PEPA [8] and has
recently been extended to allow for simulation-based analysis using Monte-Carlo
methods and discrete event simulation. For further details, see [14].
3 Modelling a simple biological system in PRISM
We now illustrate PRISM’s modelling and specification languages through an
example: the simple set of biological reactions given in Figure 1(a). We con-
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sider two proteins A and B which can undergo complexation with rate r1 and
decomplexation with rate r2. In addition, A can degrade with rate r3.
We give two alternative approaches for modelling these reactions in PRISM,
shown in Figures 1(b) and 1(c), respectively. A model described in the PRISM
language comprises a set of modules, the state of each being represented by a set
of finite-ranging variables. In approach 1 (Figure 1(b)) we use a single module
with one variable, representing the (three) possible states of the whole system
(which are listed in the italicised comments in the figure). The behaviour of this
module, i.e. the changes in states which it can undergo, is specified by a number
of guarded commands of the form [] g → r : u, with the interpretation that if the
predicate (guard) g is true, then the system is updated according to u (where
x′ = ... denotes how the value of variable x is changed). The rate at which
this occurs is r, i.e. this is the value that will be attached to the corresponding
transition in the underlying CTMC.
In approach 2 (Figure 1(c)) we represent the different possible forms that
the proteins can take (A, B and A:B) as separate modules, each with a single
variable taking value 0 or 1, representing its absence or presence, respectively. To
model interactions where the state of several modules changes simultaneously, we
use synchronisation, denoted by attaching action labels to guarded commands
(placed inside the square brackets). For example, when the bind action occurs,
variables a and b in modules A and B change from 1 to 0 and variable ab in
module AB changes from 0 to 1. In this example, the rate of each combined
transition is fully specified in module A and we have omitted the rates from
the other modules. More precisely, PRISM assigns a rate of 1 to any command
for which none is specified and computes the rate of a combined transition as
the product of the rates for each command. Note that independent transitions,
involving only a single module, can also be included, as shown by the modelling
of degradation (which only involves A), by omitting the action label.
In general, a combination of the above two modelling approaches is used. In
simple cases it is possible to use a single variable, but as the system becomes
more complex the use of separate variables and synchronisation becomes more
desirable. We will see this later in the paper.
Properties of CTMCs are specified in PRISM using an extension of the tem-
poral logic CSL. We now give a number of examples for the model in Figure 1(c).
– What is the probability that the protein A is bound to the protein B at time
instant T? (P=?[true U [T,T ] ab=1]);
– What is the probability that the protein A degrades before binding to the
protein B? (P=?[ab=0 U (a=0∧ab=0)]);
– During the first T time units, what is the expected time that the protein
A spends free? (R=?[C≤T ], assuming a reward structure which associates
reward 1 with states where the variable a equals 1 - see Figure 1(d));
– What is the expected number of times that the proteins A and B bind before
A degrades? (R=?[F (a=0∧ab=0)], assuming a reward of 1 is associated with
any transition labelled by bind - see Figure 1(e)).
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Fig. 2. Diagram showing the different possible bindings in the pathway
4 Case study: FGF
Fibroblast Growth Factors (FGF) are a family of proteins which play a key
role in the process of cell signalling in a variety of contexts, for example wound
healing. The mechanisms of the FGF signalling pathway are complex and not
yet fully understood. In this section, we present a model of the pathway which is
based on literature-derived information regarding the early stages of FGF signal
propagation and which incorporates several features that have been reported to
negatively regulate this propagation [6,21,5,20].
Our model incorporates protein-protein interactions (including competition
for partners), phosphorylation and dephosphorylation, protein complex reloca-
tion and protein complex degradation (via ubiquitin-mediated proteolysis). Fig-
ure 2 illustrates the different components in the pathway and their possible
bindings. Below is a list of the reactions included in the model. Further details
are provided in Figure 3.
1. An FGF ligand binds to an FGF receptor (FGFR) creating a complex of
FGF and FGFR.
2. The existence of this FGF:FGFR dimer leads to phosphorylation of FGFR
on two residues Y653 and Y654 in the activation loop of the receptor.
3. The dual Y653/654 form of the receptor leads to phosphorylation of other
FGFR receptor residues: Y463, Y583, Y585, Y766 (in this model we only
consider Y766 further).
4. and 5. The dual Y653/654 form of the receptor also leads to phosphorylation
of the FGFR substrate FRS2, which binds to both the phosphorylated and
dephosphorylated forms of the FGFR.
6. FRS2 can also be dephosphorylated by a phosphotase, denoted Shp2.
7. A number of effector proteins interact with the phosphorylated form of FRS2.
In this model we include Src, Grb2:Sos and Shp2.
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1. FGF binds to FGFR
FGF+FGFR ↔ FGFR:FGF (kon = 5e+8M−1s−1, koff=1e−1s−1)
2. Whilst FGFR:FGF exists
FGFR Y653 → FGFR Y653P (kcat=0.1s−1)
FGFR Y654 → FGFR Y654P (kcat=0.1s−1)
3. When FGFR Y653P and FGFR Y654P
FGFR Y463 → FGFR Y463P (kcat=70s−1)
FGFR Y583 → FGFR Y583P (kcat=70s−1)
FGFR Y585 → FGFR Y585P (kcat=70s−1)
FGFR Y766 → FGFR Y766P (kcat=70s−1)
4. FGFR binds FRS2
FGFR+ FRS2 ↔ FGFR:FRS2 (kon = 1e+6M−1s−1, koff=2e−2s−1)
5. When FGFR Y653P, FGFR Y654P and FGFR:FRS2
FRS2 Y196 → FRS2 Y196P (kcat=0.2s−1)
FRS2 Y290 → FRS2 Y290P (kcat=0.2s−1)
FRS2 Y306 → FRS2 Y306P (kcat=0.2s−1)
FRS2 Y382 → FRS2 Y382P (kcat=0.2s−1)
FRS2 Y392 → FRS2 Y392P (kcat=0.2s−1)
FRS2 Y436 → FRS2 Y436P (kcat=0.2s−1)
FRS2 Y471 → FRS2 Y471P (kcat=0.2s−1)
6. Reverse when Shp2 bound to FRS2:
FRS2 Y196P → FRS2 Y196 (kcat=12s−1)
FRS2 Y290P → FRS2 Y290 (kcat=12s−1)
FRS2 Y306P → FRS2 Y306 (kcat=12s−1)
FRS2 Y382P → FRS2 Y382 (kcat=12s−1)
FRS2 Y436P → FRS2 Y436 (kcat=12s−1)
FRS2 Y471P → FRS2 Y471 (kcat=12s−1)
FRS2 Y392P → FRS2 Y392 (kcat=12s−1)
7. FRS2 effectors bind phosphoFRS2:
Src+FRS2 Y196P ↔ Src:FRS2 Y2196P (kon = 1e+6M−1s−1, koff=2e−2s−1)
Grb2+FRS2 Y306P ↔ Grb2:FRS2 Y306P(kon = 1e+6M−1s−1, koff=2e−2s−1)
Shp2+FRS2 Y471P ↔ Shp2:FRS2 Y471P(kon = 1e+6M−1s−1, koff=2e−2s−1)
8. When Src:FRS2 we relocate/remove
Src:FRS2 → relocate out (t1/2=15min)
9. When Plc:FGFR it degrades FGFR
PLC+FGFRY 766 ↔ PLC:FGFR 766(kon = 1e+6M−1s−1, koff=2e−2s−1)
PLC:FGFR 766 → degFGFR (t1/2=60min)
10. Spry appears in time-dependent manner:
→ Spry (t1/2=15min)
11. Spry binds Src and is phosphorylated:
Spry+Src ↔ Spry Y55:Src (kon = 1e+5M−1s−1, koff=1e−4s−1)
Spry Y55:Src → Spry Y55P:Src (kcat=10s−1)
Spry Y55P+Src ↔ Spry Y55P:Src (kon = 1e+5M−1s−1, koff=1e−4s−1)
Spry Y55P+Cbl ↔ Spry Y55P:Cbl (kon = 1e+5M−1s−1, koff=1e−4s−1)
Spry Y55P+Grb2 ↔ Spry Y55P:Grb2(kon = 1e+5M−1s−1, koff=1e−4s−1)
12. phosphoSpry binds Cbl which degrades/removes FRS2
Spry Y55P:Cbl+FRS2 ↔ FRS-Ubi (kcat=8.5e−4s−1)
FRS2-Ubi → degFrs2 (t1/2=5min)
13. Spry is dephosphorylated by Shp2: (when Shp2 bound to FRS2)
Spry Y55P → Spry Y55 (kcat=12s−1)
14. Grb2 binds Sos
Grb2+Sos ↔ Grb2:Sos (kon = 1e+5M−1s−1, koff=1e−4s−1)
Fig. 3. Reaction rules for the pathway
8. and 9. These are two methods of attenuating signal propagation by removal
(i.e. relocation) of components. In step 8. if Src is associated with the phos-
phorylated FRS2, this leads to relocation (i.e. endocytosis and/or degrada-
tion of FGFR:FRS2). In step 9. if Plc is bound to Y766 of FGFR, this leads
to relocation/degradation of FGFR.
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10. The signal attenuator Spry is a known inhibitor of FGFR signalling and is
synthesised in response to FGFR signalling. Here we include a variable to
regulate the concentration of Spry protein in a time dependent manner.
11. We incorporate the association of Spry with Src and concomitant phospho-
rylation of Spry residue Y55.
12. The Y55 phosphorylated form of Spry binds with Cbl, which leads to ubiq-
uitin modification of FRS2 and a degradation of FRS2 through ubiquitin-
mediated proteolysis.
13. The Y55P form of Spry is dephosphorylated by Shp2 bound to FRS2 Y247P.
14. Grb2 binds to the Y55P form of Spry. In our model Spry competes with
FRS2 for Grb2 as has been suggested from some studies in the literature.
Note that this model is not intended to, and cannot be, a fully accurate rep-
resentation of a real-world FGF signalling pathway. Its primary purpose at this
stage of development is as a tool to evaluate biological hypotheses that are not
easily obtained by intuition or manual methods. To this end, the model is an ab-
straction as argued in [17], created to facilitate predictive “in silico” experiments
for a range of scenarios. Results of such “in silico genetics” experiments based
on simulations of a stochastic pi-calculus model of the above set of reactions are
described in [22] (see also [13]).
We explicitly draw attention to the following issues. The reactions selected
are based upon their current biological interest rather than complete understand-
ing of the components of FGF signalling. Indeed, at this stage we have ignored
many reactions that could prove significant in regulation of FGFR signalling in
real cells. However, the design permits the incorporation of further modifications
to the core model as biological understanding advances. The model is idealised
in that it does not take into account variations in composition, affinities or rate
constants that might occur in different cell types or physiological conditions.
However, a useful computational modelling approach should accommodate fu-
ture quantitative or qualitative modifications to the core model.
5 Modelling in PRISM
We now describe the specification in PRISM of the FGF model from the previous
section. We employ a combination of the two approaches discussed in Section 3.
Each of the basic elements of the pathway, including all possible compounds and
receptors residues (FGF, FGFR, FRS2, Plc, Src, Spry, Sos, Grb2, Cbl and Shp2)
is represented by a separate PRISM module. Synchronisation between modules
is used to model reactions involving interactions of multiple elements. However,
the different forms which each can take (for example, which other compounds it
is bound to) are represented by one or more variables within the module.
Our model represents a single instance of the pathway, i.e. there can be at
most one of each compound. This has the advantage that the resulting state
space is relatively small (80,616 states); however, the model is highly complex
due to the large number of different interactions that can occur in the path-
way (there are over 560,000 transitions between states). Furthermore, as will
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formula Frs = relocFrs2=0 ∧ degFrs2=0; // FRS2 not relocated or degraded
module FRS2
FrsUbi : [0..1] init 0; // ubiquitin modification of FRS2
relocFrs2 : [0..1] init 0; // FRS2 relocated
degFrs2 : [0..1] init 0; // FRS2 degraded
Y196P : [0..1] init 0;. . .Y471P : [0..1] init 0; // phosphorylation of receptors
// compounds bound to FRS2
FrsFgfr : [0..1] init 0; // 0: FGFR not bound, 1: FGFR bound
FrsGrb : [0..2] init 0; // 0: Grb2 not bound, 1: Grb2 bound, 2: Grb2:Sos bound
FrsShp : [0..1] init 0; // 0: Shp2 not bound, 1: Shp2 bound
FrsSrc : [0..8] init 0;
// 0: Src not bound 1: Src bound, 2: Src:Spry
// 3: Src:SpryP, 4: Src:SpryP:Cbl, 5: Src:SpryP:Grb
// 6: Src:SpryP:Grb:Cbl, 7: Src:SpryP:Grb:Sos, 8: Src:SpryP:Grb:Sos:Cbl
· · ·
// phosphorylation of receptors (5)
[] Frs∧Y653P=1∧Y654P=1∧FrsFgfr=1∧Y196P=0 → 0.2 : (Y196P ′=1); // Y196
· · ·
[] Frs∧Y653P=1∧Y654P=1∧FrsFgfr=1∧Y471P=0 → 0.2 : (Y471P ′=1); // Y471
// dephosphorylation of Y196 (6) - remove Src if bound
[] Frs∧FrsShp=1∧Y196P=1∧FrsSrc=0 → 12 : (Y196P ′=0);
[src rel] Frs∧FrsShp=1∧Y196P=1∧FrsSrc>0 → 12 : (Y196P ′=0)∧(FrsSrc′=0);
· · ·
// dephosphorylation of Y471 (6) - remove Shp2 since bound
[shp rel] Frs∧FrsShp=1∧Y471P=1 → 12 : (Y471P ′=0)∧(FrsShp′=0);
· · ·
// Src:FRS2→degFRS2 [8]
[] Frs∧FrsSrc>0 → 1/(15*60) : (relocFrs2 ′=1);
· · ·
// Spry55p:Cbl+FRS2→Frs-Ubi [12]
[] Frs∧FrsSrc=4,6,8 ∧ FrsUbi=0 → 0.00085 : (FrsUbi′=1);
// FRS2-Ubi→degFRS2 [12]
[] Frs∧FrsUbi=1 → 1/(5*60) : (degFrs2 ′=1);
· · ·
// Grb2+Sos↔Grb2:Sos [14]
[sos bind frs] Frs∧FrsGrb=1 → 1 : (FrsGrb′=2); // Grb:FRS2
[sos bind frs] Frs∧FrsSrc=5,6→ 1 : (FrsSrc′=FrsSrc+2);// Grb:SpryP:Src:FRS2
[sos rel frs] Frs∧FrsGrb=2 → 0.0001 : (FrsGrb′=1); // Grb:FRS2
[sos rel frs] Frs∧FrsSrc=7,8→ 0.0001 : (FrsSrc′=FrsSrc−2);// Grb:SpryP:Src:FRS2
· · ·
endmodule
Fig. 4. Fragment of the PRISM module for FRS2 and related compounds
be demonstrated later in the paper, the model is sufficiently rich to explain the
roles of the components in the pathway and how they interact. The study of a
single instance of the pathway is also motivated by the fact that the same signal
dynamics (Figure 7(a)) were obtained in [22,13] for a model where the number
of molecules of each type were initially set to 100. Fragments of the PRISM code
for the modules representing FRS2, Src and Sos are given in Figures 4, 5 and 6,
respectively. The full version is available from the PRISM web page [14].
Figure 4 shows the module for FRS2. It contains variables representing
whether FRS2 is currently: undergoing ubiquitin modification (FrsUbi); relo-
cated (relocFrs2 ); degraded (degFrs2 ); and bound to other compounds (FrsFgfr ,
FrsGrb, FrsShp and FrsSrc). It also has variables representing the phosphoryla-
tion status of each of FRS’s receptors (Y196P , . . . ,Y471P).
The first set of commands given in Figure 4 correspond to the phosphoryla-
tion of receptors in FRS (reaction 5 in Figure 3). Since the only variables that
are updated are local to this module, the commands have no action label, i.e. we
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module SRC
Src : [0..8] init 1;
// 0: Src bound to FRS2, 1: Src not bound, 2: Src:Spry
// 3: Src:SpryP, 4: Src:SpryP:Cbl, 5: Src:SpryP:Grb
// 6: Src:SpryP:Grb:Cbl, 7: Src:SpryP:Grb:Sos, 8: Src:SpryP:Grb:Sos:Cbl
// Src+FRS2196P↔Src:FRS2 (7)
[src bind] Src>0 → (Src′=0);
[src rel] Src=0 → (Src′=FrsSrc);
// Spry+Src→Spry55:Src or Spry55P+Src→Spry55P:Src (11)
[spry bind] Src=1 → 1 : (Src′=Spry+1);
// Spry+Src←Spry55:Src (11)
[spry rel] Src=2 → 0.01 : (Src′=1);
// Spry55P+Src←Spry55P:Sr (11)c
[spry rel] Src>2 → 0.0001 : (Src′=1);
// Spry55:Src→Spry55P:Src (11)
[] Src=2 → 10 : (Src′=3);
// SpryP+Cbl↔SpryP:Cbl (11)
[cbl bind src] Src=3,5,7→ 1 : (Src′=Src+1);
[cbl rel src] Src=4,6,8→ 0.0001 : (Src′=Src−1);
// SpryP+Grb↔SpryP:Grb (11)
[grb bind src] Src=3,4 → 1 : (Src′=Src+2*Grb);
[grb rel src] Src=5,6 → 0.0001 : (Src′=Src−2); // SOS not bound
[grb rel src] Src=7,8 → 0.0001 : (Src′=Src−4); // SOS bound
· · ·
endmodule
Fig. 5. PRISM module for Src and related compounds
module SOS
Sos : [0..1] init 1;
// Grb2+Sos↔Grb:Sos
[sos bind] Sos=1 → (Sos′=0); // Grb2 free
[sos bind frs]Sos=1 → (Sos′=0); // Grb2:FRS2 or to Grb2:SpryP:SRC:FRS2
[sos rel] Sos=0 → (Sos′=1); // Grb2 free
[sos rel frs] Sos=0 → (Sos′=1); // Grb2:FRS2 or to Grb2:SpryP:SRC:FRS2
· · ·
endmodule
Fig. 6. PRISM module for Sos
do not require any other module to synchronise on these commands. The guards
of these commands incorporate dependencies on the current state both of FRS2
itself and of other compounds. More precisely, FGFR must be bound to FRS2
and certain receptors of FGFR must have already been phosphorylated.
Elsewhere, in Figure 4, we see commands that use synchronisation to model
interactions with other compounds, e.g. the release of Src (the commands labelled
src rel) and the binding and release of Sos (the commands labelled sos bind frs
and sos rel frs). Note the corresponding commands in modules SRC (Figure 5)
and SOS (Figure 6). In each of these cases, as discussed in Section 3, the rate of
the combined interaction is specified in the FRS2 module and is hence omitted
from the corresponding commands in SRC and SOS . Also, in the module for
Sos (Figure 6), there are different action labels for the binding and release of
Sos with Grb2; this is because Grb2 can be either free or bound to a number
of different compounds when it interacts with Sos. For example, Grb2 can be
bound to Frs2 (through reaction 7) or Spry (through reaction 11), and Spry can
in turn be bound to Src, which can also be bound to FRS2.
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Notice how, in the commands for binding and unbinding of Src with FRS2 in
Figure 4 (labelled sos bind frs and sos rel frs), we can use the value of FrsSrc
to update the value of Src, rather than separating each case into individual
commands. Also worthy of note are the updates to Src in Figure 5 when either
Grb2 or Grb2:Sos bind to Src. To simplify the code, we have used a single
command for each of these possible reactions, and therefore updates which either
increment or decrement the variable Src by 2 or 4 (the variable Grb takes value
1 if Grb2 is not bound to Sos and value 2 if Sos is bound).
6 Property specification
Our primary goal in this case study is to analyse the various mechanisms pre-
viously reported to negatively regulate signalling. Since the binding of Grb2 to
FRS2 serves as the primary link between FGFR activation and ERK signalling,
we examine the amount of Grb2 bound to FRS2 as the system evolves. In ad-
dition, we investigate the different causes of degradation which, based on the
system description, can be caused by one of the following reactions occurring:
– when Src:FRS2 is present, FRS2 is relocated (reaction 8);
– when Plc:FGFR is present, it degrades FGFR (reaction 9);
– when phosphoSpry binds to Cbl, it degrades FRS2 (reaction 12).
Below, we present a list of the various properties of the model that we have
analysed, and the form in which they are supplied to the PRISM tool. For the
latter, we define a number of atomic propositions, essentially predicates over the
variables in the PRISM model, which can be used to identify states of the model
that have certain properties of interest. These include agrb2 , which indicates that
Grb2 is bound to FRS2 (i.e. those states where the variable FrsGrb of Figure 4 is
greater than zero), and asrc , aplc and aspry , corresponding to the different causes
of degradation/relocation given above. For properties using expected rewards
(with the R=?[·] operator), we also explain the reward structure used.
A. What is the probability that Grb2 is bound to FRS2 at the time instant T?
(P=?[true U [T,T ] agrb2 ]);
B. What is the expected number of times that Grb2 binds to FRS2 by time T?
(R=?[C≤T ], where a reward of 1 is assigned to all transitions involving Grb2
binding to FRS2);
C. What is the expected time that Grb2 spends bound to FRS2 within the first
T time units? (R=?[C≤T ], where a reward of 1 is assigned to states where
Grb2 is bound to FRS2, i.e. those satisfying atomic proposition agrb2 );
D. What is the long-run probability that Grb2 is bound to FRS2? (S=?[agrb2 ]);
E. What is the expected number of times Grb2 binds to FRS2 before degradation
or relocation occurs? (R=?[F (asrc∨aplc∨aspry)], with rewards as for B);
F. What is the expected time Grb2 spends bound to FRS2 before degradation or
relocation occurs? (R=?[F (asrc∨aplc∨aspry)], with rewards as for C);
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G. What is the probability that each possible cause of degradation/relocation has
occurred by time T? (e.g. P=?[¬(asrc∨aplc∨aspry) U [0,T ] asrc ] in the case Src
causes relocation);
H. What is the probability that each possible cause of degradation/relocation
occurs first? (e.g. P=?[¬(asrc∨aplc∨aspry) U aplc ] in the case when Plc causes
degradation);
I. What is the expected time until degradation or relocation occurs in the path-
way? (R=?[F (asrc∨aplc∨aspry)] where all states have reward 1).
7 Results and analysis
We used PRISM to construct the FGF model described in Section 5 and analyse
the set of properties listed in Section 6. This was done for a range of different
scenarios. First, we developed a base model, representing the full system, in
which we suppose that initially FGF, unbound and unphosphorylated FGFR,
unphosphorylated FRS2, unbound Src, Grb2, Cbl, Plc and Sos are all present in
the system (Spry arrives into the system with the half-time of 10 minutes).
Subsequently, we performed a series of “in silico genetics” experiments on the
model designed to investigate the roles of the various components of the activated
receptor complex in controlling signalling dynamics. This involves deriving a
series of modified models of the pathway where certain components are omitted
(Shp2, Src, Spry or Plc), and is easily achieved in a PRISM model by just
changing the initial value of the component under study. For example, to remove
Src from the system we just need to change the initial value of the variable Src
from 1 to 0 (see Figure 5).
For each property we include the statistics for 5 cases: for the full pathway and
for the pathway when either Shp2, Src, Spry or Plc is removed. Figures 7(a)–(c)
show the transient behaviour (i.e. at each time instant T ) of the signal (binding
of Grb2 to FRS2) for the first 60 minutes, namely properties A, B and C from
the previous section. Table 1 gives the the long-run behaviour of the signal, i.e.
properties D, E and F. The latter three results can be regarded as the values
of the first three in “the limit”, i.e. as either T tends to infinity or degradation
occurs. Figures 7(d)–(f) show the transient probability of each of the possible
causes of relocation or degradation occurring (property G). Table 2 shows the
results relating to degradation in the long-run (properties H and I).
We begin with an analysis of the signal (binding of Grb2 to FRS2) in the
full model, i.e. see the first plot (“full model”) in Figure 7 and the first lines of
Tables 1 and 2. The results presented demonstrate that the probability of the
signal being present (Figure 7(a)) shows a rapid increase, reaching its maximum
level at about 1 to 2 minutes. The peak is followed by a gradual decrease in
the signal, which then levels off at a small non-zero value. In this time interval
Grb2 repeatedly binds to FRS2 (Figure 7(b)) and, as time passes, Grb2 spends
a smaller proportion of time bound to FRS2 (Figure 7(c)).
The rapid increase in the signal is due the relevant reactions (the binding of
Grb2 to FRS2 triggered by phosphorylation of FRS2, which requires activated
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Fig. 7. Transient numerical results
FGFR to first bind to FRS2) all occurring at very fast rates. On the other
hand, the decline in the signal is caused either by dephosphorylation of FRS2
(due to Shp2 being bound to FRS2) or by relocation/degradation of FRS2.
Dephosphorylation of FRS2 is both fast and allows Grb2 to rebind (as FRS2 can
become phosphorylated again). The overall decline in signal is due to relocation
of FRS2 caused by bound Src which takes a relatively long time to occur (Table 2
and Figure 7(d)). Degradation caused by Spry has little impact since it is not
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probability expected no. expected time
bound of bindings bound (min)
full model 7.54e-7 43.1027 6.27042
no Shp2 3.29e-9 10.0510 7.78927
no Src 0.659460 283.233 39.6102
no Spry 4.6e-6 78.3314 10.8791
no Plc 0.0 51.5475 7.56241
Table 1. Long run and expected reachability properties for the signal
probability of degradation/relocation expected
Src:FRS2 Plc:FGFR Spry:Cbl time (min)
full model 0.602356 0.229107 0.168536 14.0258
no Shp2 0.679102 0.176693 0.149742 10.5418
no Src - 1.0 0.0 60.3719
no Spry 0.724590 0.275410 - 16.8096
no Plc 0.756113 - 0.243887 17.5277
Table 2. Probability and expected time until degradation/relocation in the long
run
present from the start and, by the time it appears, it is more likely that Grb2 is no
longer bound or Src has caused relocation (Table 2, Figure 7(d) and Figure 7(f)).
The fact that the signal levels out at a non-zero value (Table 1) is caused
by Plc degrading the FGF receptor bound to FRS2 and Grb2. More precisely,
after FGFR is degraded by Plc, no phosphorylation of partner FRS2 residues
is possible. The signal stays non-zero since neither Src-mediated relocation and
degradation, nor Shp-mediated dephosphorylation, are possible when respective
FRS2 residues are not active. The non-zero value is very small because it is more
likely that Src has caused relocation (Table 2). The repeated binding of Grb2 to
FRS2 (Figure 7(b)) is caused by the dephosphorylation of FRS2, which is soon
phosphorylated again and allows Grb2 to rebind. The decrease in the proportion
of time that Grb2 is bound to FRS2 is due to the probability of FRS2 becoming
relocated/degraded increasing as time passes (Figure 7(d)–(f)).
Next, we further illustrate the role of the components by analysing models
in which different elements of the pathway are not present.
Shp2. Figure 7(a) shows that the peak in the signal is significantly larger
than that seen under normal conditions. By removing Shp2 we have removed, as
explained above, the fast reaction for the release of Grb2 from FRS2, and this
justifies the larger peak. The faster decline in the signal is due to there being
a greater chance of Src being bound (as Shp2 causes the dephosphorylation of
FRS2, it also causes the release of Src from FRS2), and hence the increased
chance relocation (Figure 7(d) and Table 2). These observations are also the
cause for the decrease in the time until degradation/relocation when Shp2 is
removed (Table 2) and the fact that the other causes of degradation/relocation
are less likely (Figures 7(e)–(f) and Table 2). Dephosphorylation due to bound
Shp2 was responsible for the large number of times that Grb2 and FRS2 bind
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(and unbind) in the original model; we do not see such a large number of bindings
once Shp2 is removed (Figure 7(b) and Table 1).
Src. As Figure 7(a) demonstrates, the suppression of Src is predicted to
have a major impact on signalling dynamics: after a fast increase, the signal
fails to decrease substantially. This is supported by the results presented in
both Figures 7(d)–(f) and Table 2 which show that Src is the main cause of
signal degradation, and by removing Src the time until degradation or relocation
greatly increases. The failure of Spry to degrade the signal (Figure 7(f) and
Table 2) is attributed to its activation being downstream of Src. Note that, this
also means that Plc is the only remaining cause of degradation.
Spry. The model fails to reproduce the role of Spry in inhibiting the ac-
tivation of the ERK pathway by competition for Grb2:Sos. More precisely, our
results show that the suppression of Spry does not result in signal reduction. This
can be explained by the differences in system designs: under laboratory condi-
tions the action of Spry is measured after Spry is over-expressed, whereas, under
normal physiological conditions, Spry is known to arrive slowly into the system.
Removing Spry removes one of the causes of degradation, and therefore increases
the other causes of degradation/relocation (Figures 7(d)–(e) and Table 2). More-
over, the increase in the probability of Plc causing degradation/relocation leads
to an increase in the chance of Grb2 and FRS2 remaining bound (Table 2).
Plc. While having a modest effect on transient signal expression, the main
action of Plc removal is to cause the signal to stabilise at zero (Table 1). This is
due to Plc being the only causes of degradation/relocation not relating to FRS2.
The increase in time until degradation (Table 2) is also attributed to the fact
that, by removing Plc, we have eliminated one of the possible causes of degra-
dation. This also has the effect that the other causes of relocation/degradation
are more likely (Figure 7(d), Figure 7(f) and Table 2).
8 Conclusions
In this paper we have shown that probabilistic model checking can be a useful
tool in the analysis of biological pathways. The technique’s key strength is that
it allows the calculation of exact quantitative properties for system events occur-
ring over time, and can therefore support a detailed, quantitative analysis of the
interactions between the pathway components. By developing a model of a com-
plex, realistic signalling pathway that is not yet well understood, we were able
to demonstrate, firstly, that the model is robust and that its predictions agree
with biological data [22,13] and, secondly, that probabilistic model checking can
be used to obtain a wide range of quantitative measures of system dynamics,
thus resulting in deeper understanding of the pathway.
We intend to perform further analysis of the FGF pathway, including an
investigation into the effect that changes to reaction rates and initial concentra-
tions will have on the pathway’s dynamics. Future work will involve both com-
paring this probabilistic model checking approach with simulation and ODEs,
and also investigation of how to scale the methodology yet further.
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